The Florida ADAP (AIDS Drug Assistance Program) crisis drew national attention in early 2026. But Florida is not the only state facing strain in HIV program funding.
In Pennsylvania, changes to the Special Pharmaceutical Benefits Program (SPBP), supported through Ryan White Part B funding, are limiting access to medications for some patients. At the federal level, the proposed 2027 budget includes significant reductions to several HIV/AIDS programs, including the Minority HIV/AIDS Fund and the Ryan White HIV/AIDS Dental Program.
Pennsylvania: A Quieter Shift with Real Impact
Pennsylvania’s SPBP has long served as a critical access point for HIV medications. Recent changes to the program are narrowing access and creating new barriers for patients who rely on it.
Unlike Florida, where funding changes triggered emergency action and widespread visibility, Pennsylvania’s adjustments have received far less attention. However, the impact at the patient level remains significant: reduced access, increased uncertainty, and greater reliance on alternative coverage pathways.
Federal Outlook: Continued Pressure on HIV Programs
Analysis from AIDS United indicates that the proposed 2027 federal budget includes the elimination of funding for several programs, including:
- The Minority HIV/AIDS Fund
- The Ryan White HIV/AIDS Dental Program
- Special Projects of National Significance
These programs have historically supported targeted care, innovation, and services for underserved populations—particularly in areas not fully reached by core Ryan White Part A and Part B funding.
While the budget process is ongoing, the direction signals continued pressure on the broader HIV funding landscape.
Florida’s Fix is Important, but Temporary
In late March 2026, Governor Ron DeSantis signed House Bill 697, allocating $31 million to restore access to Florida’s ADAP program.
This action stabilized access in the near term, but the timeline matters: the funding extends only through June 30, 2026. As the next budget cycle approaches, long-term sustainability remains uncertain without structural changes.
Why More Providers Are Looking at Structural Solutions
As funding variability increases, many Ryan White providers are reassessing how dependent their care models are on annual appropriations and state-level decisions.
Programs that rely exclusively on grant-funded medication access may face increasing volatility. In contrast, models that incorporate diversified coverage pathways can provide greater continuity for patients.
Where PIAP Fits
A well-designed Premium Insurance Assistance Program (PIAP) helps transition eligible patients to ACA Marketplace coverage, where medications are covered through commercial formularies.
This approach can:
- Reduce reliance on ADAP enrollment limits and funding cycles
- Provide more consistent access to medications
- Create a more predictable reimbursement structure
American Exchange supports Ryan White providers in designing and managing PIAP programs, including enrollment, plan selection, and ongoing support.
When funding environments shift, patients enrolled in coverage-based models are less exposed to disruptions tied to program-level changes. For providers, the question is shifting from “How do we respond to funding changes?” to “How do we build models that are more resilient to them?”.
Schedule time to learn how PIAP can support long-term access and stability for your patients.
Sources
DeSantis signs law to restore HIV medication access through June – The 19th News
